Renal Denervation Prevents Heart Failure Progression Via Inhibition of the Renin-Angiotensin System Article

Full Text via DOI: 10.1016/j.jacc.2018.08.2186 PMID: 30466519 Web of Science: 000450586600008

Cited authors

  • Sharp, Thomas E., III; Polhemus, David J.; Li, Zhen; Spaletra, Pablo; Jenkins, J. Stephen; Reilly, John P.; White, Christopher J.; Kapusta, Daniel R.; Lefer, David J.; Goodchild, Traci T.


  • BACKGROUND Previously, we have shown that radiofrequency (RF) renal denervation (RDN) reduces myocardial infarct size in a rat model of acute myocardial infarction (MI) and improves left ventricular (LV) function and vascular reactivity in the setting of heart failure following MI.; OBJECTIVES The authors investigated the therapeutic efficacy of RF-RDN in a clinically relevant normotensive swine model of heart failure with reduced ejection fraction (HFrEF).; METHODS Yucatan miniswine underwent 75 min of left anterior descending coronary artery balloon occlusion to induce MI followed by reperfusion (R) for 18 weeks. Cardiac function was assessed pre- and post-MI/R by transthoracic echocardiography and every 3 weeks for 18 weeks. HFrEF was classified by an LV ejection fraction <40%. Animals who met inclusion criteria were randomized to receive bilateral RF-RDN (n = 10) treatment or sham-RDN (n = 11) at 6 weeks post-MI/R using an RF-RDN catheter.; RESULTS RF-RDN therapy resulted in significant reductions in renal norepinephrine content and circulating angiotensin I and II. RF-RDN significantly increased circulating B-type natriuretic peptide levels. Following RF-RDN, LV end-systolic volume was significantly reduced when compared with sham-treated animals, leading to a marked and sustained improvement in LV ejection fraction. Furthermore, RF-RDN improved LV longitudinal strain. Simultaneously, RF-RDN reduced LV fibrosis and improved coronary artery responses to vasodilators.; CONCLUSIONS RF-RDN provides a novel therapeutic strategy to reduce renal sympathetic activity, inhibit the renin-angiotensin system, increase circulating B-type natriuretic peptide levels, attenuate LV fibrosis, and improve left ventricular performance and coronary vascular function. These cardioprotective mechanisms synergize to halt the progression of HFrEF following MI/R in a clinically relevant model system. (J Am Coll Cardiol 2018; 72: 2609-21) (c) 2018 by the American College of Cardiology Foundation.

Publication date

  • 2018

International Standard Serial Number (ISSN)

  • 0735-1097

Start page

  • 2609

End page

  • 2621


  • 72


  • 21